Passage BIO

PASGNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$14.114 M

$4.40 +0.00%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$45.5M

Loss-making

Shares outstanding

3,207,810

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#142Jasper TherapeuticsJSPR$19.9M
#143PluriPLUR$19.6M
#144Passage BIOPASG$14.1M
#145Intensity TherapeuticsINTS$11.2M
#146BioCardiaBCDA$11.1M

Where these numbers come from

Share counts and financials for Passage BIO are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.